Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Danish biotech Nuevolution completes SEK250mm IPO

23 May 2019

Executive Summary

Nuevolution AS (small-molecule drug screening) completed an initial public offering in Sweden and Denmark of 14.2mm shares (including the overallotment) at SEK 17.50, resulting in gross proceeds of SEK250mm ($29.7mm), up-sized from the original SEK225mm amount. The company has applied to trade its shares on Nasdaq's First North Premier exchange, which does not have the same legal status as a regulated marketplace. The offering could potentially be the largest on this exchange so far this year.
Deal Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By